EP0325343A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
L-glutamic acid derivatives
Assignee: Eli Lilly and Co
•
Filing: 1989-01-05
•
Granted: —
•
Expires: 2009-01-05
Abstract
Abstract Pyrimidin-5-yl derivatives of L-glutamic acid are anti-neoplastic agents. A typical embodiment is N-(4-[4-(2,4-diamino-6-hydroxypyrimidin-5-yl)-butyl]-benzoyl)-L-glutamic acid.
Inventors
- 👤 Edward C. Taylor
- 👤 Philip M. Harrington
- 👤 Chuan Shih
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 10:48
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/48; A; A61; A61P; A61P35/00; C07D239/50; C07D239/52; C07D239/54; C07D239/545
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
74 words
A compound of the formula: in which each of X and Y, independently of the other is hydroxy or amino; Z is 1,4-phenylene unsubstituted or substituted with one to four chlorine or fluorine atoms; cyclohexa-1,4-diyl; or a straight or branched chain alkylene group of 2 to 5 carbon atoms; n has a value of 2 to 6; and the configuration about the carbon atom designated * is L; and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
74 words
A compound of the formula: in which each of X and Y, independently of the other is hydroxy or amino; Z is 1,4-phenylene unsubstituted or substituted with one to four chlorine or fluorine atoms; cyclohexa-1,4-diyl; or a straight or branched chain alkylene group of 2 to 5 carbon atoms; n has a value of 2 to 6; and the configuration about the carbon atom designated * is L; and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
15 words
A compound according to claim 1 in which Y is amino and X is hydrogen.
Claim 4
Dependent Claim
14 words
A compound according to claim 1 in which both X and Y are hydroxy.
Claim 5
Dependent Claim
14 words
A compound according to claim 1 in which both X and Y are amino.
Claim 6
Dependent Claim
14 words
A compound according to claim 1 in which Z is 1,4-phenylene, cyclohexa-1,4-diyl; or tetramethylene.
Claim 7
Dependent Claim
11 words
A compound according to claim 2 in which Z is 1,4-phenylene.
Claim 8
Dependent Claim
11 words
A compound according to claim 2 in which Z is cyclohexa-1,4-diyl.
Claim 9
Dependent Claim
11 words
A compound according to claim 4 in which Z is tetramethylene.
Claim 10
Dependent Claim
15 words
A compound according to claim 1 in which -(C n H 2n )- is tetramethylene.
Claim 11
Dependent Claim
32 words
The method of combating neoplastic growth in a mammal which comprises administering to the mammal in a single or multiple dose regimen an effective amount of a compound according to claim 1.
Claim 12
Dependent Claim
47 words
A pharmaceutical composition for combating neoplastic growth in a mammal which comprises an amount of a compound according to claim 1 which upon administration to the mammal in a single or multiple dose regimen is effective to combat said growth, in combination with a pharmaceutically acceptable carrier.
Claim 13
Dependent Claim
31 words
A compound according to claim 1 which has the formula: in which n has a value of 3 to 5 and the configuration about the carbon atom designated * is L.
Claim 14
Dependent Claim
10 words
The compound according to claim 12 which is N-(4-[4-(2,4-diamino-6-hydroxypyrimidin-5-yl)butyl]-benzoyl)-L-glutamic acid.
Claim 15
Dependent Claim
32 words
The method of combating neoplastic growth in a mammal which comprises administering to the mammal in a single or multiple dose regimen an effective amount of a compound according to claim 12.
Claim 16
Dependent Claim
47 words
A pharmaceutical composition for combating neoplastic growth in a mammal which comprises an amount of a compound according to claim 12 which upon administration to the mammal in a single or multiple dose regimen is effective to combat said growth, in combination with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.